A new UK study will seek to understand the immune response to COVID-19 vaccinations in patients with certain immunosuppressed conditions.
The trial, called the OCTAVE trial, is funded by the Medical Research Council (MRC), and is a collaborative research project involving groups in the Universities of Glasgow, Birmingham, Oxford, Liverpool, Imperial College London and Leeds Teaching Hospitals NHS Trust.
Patients with end stage kidney disease have a poor prognosis following infection with COVID, with one in every five infected dialysis patients in the UK having died. Dr Michelle Willicombe Imperial study co-lead
Researchers will build on years of experience in understanding the immune system in the context of chronic conditions, to better determine the effectiveness of COVID-19 vaccines in these clinically at-risk patient groups.
People with cancer, inflammatory arthritis, diseases of the kidney or liver or who are having a stem cell transplant may be at increased risk of the more severe complications of COVID-19 infection.
As a result, the rollout of vaccines is especially welcome for these vulnerable groups.
However, these underlying medical conditions and the treatment that such patients receive as part of their care, may weaken the immune system.
Current evidence shows that people with these medical conditions may not obtain optimal protection from established vaccines. Patients with significant underlying diseases were generally excluded from COVID-19 vaccine studies to date – it is now important to confirm that the COVID-19 vaccines work well in such conditions.
Thousands of patients studied across the UK
The OCTAVE study will investigate the effectiveness of COVID-19 vaccines being used in the UK in 2021, in up to 5,000 people within these patient populations.
Using a variety of state-of-the-art immune tests performed on blood samples taken before and/or after COVID-19 vaccination, researchers will determine patients’ COVID-19 immune response and therefore the likelihood that vaccines will fully protect these groups from SARS-CoV-2 infection.
Researchers have begun recruiting patients at sites across the UK and will compare results from the study group against control groups of healthy people, without these underlying diseases, who also received COVID-19 vaccines. The OCTAVE study will evaluate patients who receive COVID-19 vaccines as part of the national vaccination programme.
Professor Iain McInnes, Head of the College of Medical, Veterinary and Life Sciences at the University of Glasgow who leads the OCTAVE study, said: “We urgently need to understand if patient populations with chronic conditions such as cancer, inflammatory arthritis and kidney and liver disease are likely to be well-protected by current COVID-19 vaccines. The OCTAVE study will give us invaluable new data to help us answer questions of this kind from our patients and their families.”
Scientists do not yet know how long COVID-19 vaccines provide immunity for, and there may be an ongoing vaccination requirement against the disease for years to come. This may be especially so in people with weakened immune systems, due to drug treatments and underlying disease. Results from the OCTAVE study will help to inform how best to vaccinate patients with chronic conditions, and protect them from SAAR-CoV-2 infection.
Dr Michelle Willicombe is the co-lead of the Imperial College London arm of the trial, together with Dr David Thomas. The Imperial section of the trial will investigate the effectiveness of the COVID-19 vaccine in people with kidney disease.
Dr Willicombe, from Imperial's Department of Immunology and Inflammation, said: "Patients with end stage kidney disease (ESKD) have a poor prognosis following infection with COVID, with one in every five infected dialysis patients in the UK having died. Despite these risks, our dialysis have been unable to shield to protect themselves, as they have to attend hospital for regular treatment throughout the pandemic. Therefore, knowing if COVID vaccines are effective in patients with ESKD, whether on dialysis or transplanted, will be extremely important for our patients."
Those most at risk will receive the best protection
Professor Fiona Watt, Executive Chair of the Medical Research Council, which funded the study, said: “This study is investigating the response to the new COVID-19 vaccines in people whose immune systems make them more vulnerable to COVID-19 and other infections. This will help ensure that those more at risk from infection receive the best protection possible.”
The OCTAVE study is sponsored by the University of Birmingham and is being run by the University’s Cancer Research UK Clinical Trials Unit (CRCTU).
University of Birmingham Professor Pam Kearns, Director of the CRCTU, said: “We are pleased to be supporting this important nationally collaborative study that will inform the best use of the COVID-19 vaccines to protect these vulnerable patients.”
Adapted from a press release from The University of Glasgow
Article text (excluding photos or graphics) © Imperial College London.
Photos and graphics subject to third party copyright used with permission or © Imperial College London.